Does Mississippi Medicaid Cover Wegovy and Zepbound? Coverage, Criteria and Who Stays On

Yes. Mississippi Medicaid has covered selected weight-loss drugs since July 1, 2023, with prior authorization, and as of November 2026 its criteria for those drugs were last updated July 1, 2026.^[1][2] Wegovy, Zepbound, Saxenda and the Foundayo pill are all preferred on the state’s November 2026 drug list.^[15] A study by university researchers and Medicaid staff found that only about a quarter of adults who started were still taking the drug regularly a year later.^[4]

Does Mississippi Medicaid cover Wegovy and Zepbound for weight loss?

Mississippi Medicaid does, which sets it apart in its region. Under federal law, each state may decide whether Medicaid pays for weight-loss drugs.^[6] In 2023 Mississippi asked CMS to add “selected drugs that treat obesity,” and CMS approved the change effective July 1, 2023, with the state plan saying the covered drugs are those “listed on the state’s website.”^[1] Neighboring Louisiana and Alabama still exclude weight-loss use. Our explainer on how states choose on Medicaid weight-loss coverage covers the federal side.

The list on the state’s website is the anti-obesity prior authorization packet. As archived on July 3, 2026, the Division’s prior authorization page showed that packet updated July 1, 2026, next to a separate packet for Wegovy in the liver disease MASH dated October 30, 2025.^[2]

Which drugs are covered, and from what age?

The January 2025 criteria, the latest version we could open, named Saxenda and Wegovy as preferred from age 12 and Xenical as non-preferred. Qsymia was left out because its maker does not pay federal Medicaid rebates, and phentermine because it has not shown longer-term health benefits.^[3] The November 2026 drug list now names Foundayo, Saxenda, Wegovy and Zepbound as preferred, with orlistat, Xenical and generic liraglutide non-preferred, and it caps each drug at a month’s supply.^[15] A notice from the state’s October 27, 2026 drug committee meeting proposes moving Saxenda to non-preferred on January 1, 2027, pending approval.^[16] Search-engine copies of the July 2026 criteria give the ages as 12 and up for Saxenda or Wegovy and 18 and up for Foundayo and Zepbound. That fits the labels: Wegovy is approved from age 12, while Zepbound and Foundayo are approved for adults.^[10][11][12]

What BMI do you need for Mississippi Medicaid to cover a GLP-1?

For adults, a BMI of 30 or more qualifies on its own. In the January 2025 version, a lower BMI could qualify with at least one weight-related condition confirmed in the record: high blood pressure or high cholesterol shown by prescription claims, diabetes or prediabetes, sleep apnea on a prior sleep study, heart disease, or fatty liver disease.^[3] Search copies of the July 2026 file give the lower band as 27 to 29 with a comorbidity. Teenagers 12 to 17 qualified for Wegovy at a BMI above the 95th percentile for age and sex.^[3]

Some rules ran through every version we saw. Only one weight-loss drug is covered at a time, and the November 2026 list sends any request to combine one with a diabetes GLP-1 to clinical review,^[15] and the state does not pay for these drugs during pregnancy or while breastfeeding.^[3] The first request carries a treatment plan with a six-month goal, and the prescriber confirms that diet and activity counseling took place.^[3]

How does renewal work?

In the January 2025 criteria, approvals ran six months, and renewal depended on three things: steady refills (three paid claims in the past 105 days), reaching a target dose (1.7 mg or 2.4 mg for Wegovy), and weight loss.^[3] Losing 5% or more earned six more months. A loss of 1% to 4% could earn three months if titration had been delayed by side effects or illness, and a loss under 1% meant denial, with a suggestion to try another covered drug.^[3] The November 2026 drug list says Wegovy, Zepbound and Foundayo go through the state’s automated prior authorization check, that a manual request may be needed when that check is not met, and that reauthorization after 12 months needs a manual request.^[15] The same entry also says “All agents MANUAL PA required,” so a prescriber should be ready to file a manual request for any of these drugs.^[15] Search copies of the July 2026 criteria also describe 12-month approvals and a 5% check; ask the plan for the exact renewal rules before the first approval runs out.

How many Mississippi Medicaid members stay on a GLP-1?

Fewer than the trials would suggest. A study by University of Mississippi researchers and Division of Medicaid staff followed 3,968 adults who started a weight-loss GLP-1 between July 2023 and June 2025.^[4] It is a retrospective look at claims, not a trial. Most were women (92.5%) and about half were Black.^[4]

Starting in 2023, younger age, Black race, type 2 diabetes and heart disease were linked with worse patterns, while being in a managed care plan and having high blood pressure were linked with better ones.^[4] At its March 2026 meeting, the state’s drug review board heard that people who started in 2025 did substantially better than the 2023 group, when shortages interrupted supply, but still trailed published figures. Board members raised the need for more flexible dose increases for people struggling with side effects, and the board voted for the Division to look for the barriers.^[5] Our look at what people pay and whether they stay on GLP-1s puts these numbers next to other groups.

Does Mississippi Medicaid cover Wegovy for MASH?

It has a separate prior authorization packet for that use, dated October 30, 2025.^[2] We could not open it. Wegovy’s label covers noncirrhotic MASH with moderate to advanced fibrosis (stages F2 to F3) in adults, so expect the request to need proof of the fibrosis stage.^[11] Our page on GLP-1s and fatty liver disease covers the evidence. We found no separate heart or sleep apnea packet; people with those conditions and a qualifying BMI generally fall under the main weight-loss criteria, where sleep apnea and heart disease were listed as qualifying conditions in 2025.^[2][3]

How do you file, and how do appeals work?

Gainwell Technologies handles pharmacy prior authorization for the state. The prescriber files through Gainwell’s provider portal or by fax at 866-644-6147; the line is 833-660-2402.^[2] The January 2025 form covered fee-for-service, MississippiCAN managed care and CHIP members alike.^[3] People with type 2 diabetes use the diabetes GLP-1s instead, where the November 2026 list prefers Mounjaro, Ozempic, Trulicity, Victoza and Byetta.^[15] The state’s page also links a pharmacy reconsideration form for a request that was turned down.^[2]

For a formal appeal, federal rules give a managed care member 60 days from the plan’s notice to appeal to the plan, then 90 to 120 days from the plan’s decision to request a state fair hearing.^[7][8] A fee-for-service hearing request has to be allowed at least a reasonable window, capped at 90 days from the notice.^[9] Use the date on your notice. Our walkthrough of prior authorization and appeals covers what to send, and the Mississippi state page keeps the basics together.

What if you do not qualify?

Cash is the fallback, and Lilly’s savings card excludes Medicaid members.^[13] In the figures we track, Novo Nordisk sells most Wegovy pen doses for $349 a month, and Lilly charges $299 for Zepbound at the starting dose, $399 at 5 mg and $449 at 7.5 mg and up when each refill comes within 45 days.^[13][14] Check each program’s terms on government coverage first. Our list of the least expensive ways to pay cash for a GLP-1 compares them.